INTRODUCTION
T helper 17 (Th17) cells promote inflammation and tissue injury and are associated with autoimmune diseases. However, they also play a role in pathogen resistance (Weaver et al., 2007) . With the aid of transforming growth factor-b (TGF-b),interleukin-6 (IL-6), and other cytokines, antigen-presenting cells (APCs), such as dendritic cells (DCs) and macrophages, trigger development of Th17 cells (Bettelli et al., 2006) . Recent studies revealed that TGF-b signaling is mediated by integrin molecules on APCs, which enables direct delivery of biologically active TGF-b into naive T cells (Acharya et al., 2010; Melton et al., 2010) . Integrin-triggered TGF-b signaling results in activation of ROR family transcription factors that direct Th17 cell differentiation and production of the signature cytokine IL-17 (Ivanov et al., 2006; Yang et al., 2008) . It also activates Treg generation (Travis et al., 2007) .
One of the best-studied autoimmune diseases causally associated with Th17 cells is experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS). MS is an inflammatory disease of the central nervous system (CNS) that involves demyelination and neuronal injury (Hauser and Oksenberg, 2006; Steinman and Zamvil, 2006) . Mice lacking RORa, RORgt, and IL-17 are largely resistant to EAE (Ivanov et al., 2006; Komiyama et al., 2006) . Correlating with results in the mouse, Th17 cells and IL-17 are present in the CNS of MS patients (Axtell et al., 2010) . In addition to Th17 cells, Th1 cells play substantive roles in EAE, causing CNS lesions distinct from those by Th17 cells (Axtell et al., 2010; Kroenke et al., 2008; Stromnes et al., 2008) . Involvement of Th1 cells in MS is also documented, adding to the similarity of EAE with MS (Lovett-Racke et al., 2011) . Th17 cells, once developed, further proliferate in lymph nodes and then in the CNS, the processes dependent on IL-23, a cytokine of the IL-12 family, produced largely by macrophages and microglia (Becher et al., 2003; Chen et al., 2006; Cua et al., 2003) . The classical IL-12p70 supports the development and expansion of Th1 cells (Kroenke et al., 2008) . Conversely, development of Th17 cells and EAE is suppressed by IL-27, another IL-12 family cytokine (Batten et al., 2006; Bettelli et al., 2006; Stumhofer et al., 2006) . Although infiltrating T cells and APCs initiate CNS inflammation, activation of the resident microglia worsens the disease by increasing inflammation and neuronal damage (Sørensen et al., 1999; Starossom et al., 2012) .
Despite much progress, the etiology of MS has remained elusive. This is partly attributable to the multiplicity of pathways that affect the disease (Hauser and Oksenberg, 2006) . In this context, genome-wide SNP analyses shed new light on understanding the onset and progression of MS as they identify susceptibility factors likely influencing the disease (De Jager et al., 2009; Disanto et al., 2012; Beecham et al., 2013) . Besides classically known HLA genes, a number of additional genes have been designated as MS susceptibility factors, including IRF8 (De Jager et al., 2009; Disanto et al., 2012) . IRF8 is a transcription factor of the IRF family known to direct development of macrophages and DCs . It drives transcription of IL-12p40 and type I interferons in these cells, thus playing essential roles in defense against various pathogens (Tailor et al., 2008; Hambleton et al., 2011; Chang et al., 2012) . Additionally, IRF8 regulates activities in T and B lymphocytes (Feng et al., 2011; Miyagawa et al., 2012; Ouyang et al., 2011) . The SNP regions associated with MS susceptibility map to the 3 0 noncoding region of the IRF8 gene, suggesting that regulation of IRF8 transcription accounts for MS susceptibility. Nevertheless, little information is available as to how IRF8 affects the course of MS. We show here that Irf8 À/À mice are protected from EAE, and that IRF8 expressed in APCs, rather than T lymphocytes, causes the disease by facilitating the onset and expansion of effector T cells and promoting microglia-based neuroinflammation.
RESULTS

Irf8 -/-Mice Are Resistant to EAE
To study the role of IRF8 in EAE pathogenesis, wild-type (WT) and Irf8 À/À mice were injected with MOG 35-55 (hereafter MOG) and clinical signs of the EAE were scored on a daily basis ( Figure 1A ). All WT mice exhibited clear signs of EAE from days 7-9, which peaked on days 17-20, followed by a slight decline thereafter. In contrast, Irf8 À/À mice were completely resistant to EAE, and showed no clinical signs. Histopathological analysis of spinal cords of WT mice revealed typical EAE features with mononuclear cell infiltration, gliosis, neuronal damage, and demyelination, whereas spinal cords of Irf8 À/À appeared to be normal (Figures 1B; see Figure S1A available online). EAE in Irf8 À/À mice was further analyzed by quantitative magnetic resonance imaging (MRI) to detect blood-brain barrier (BBB) disruption and tissue contrasts (Schellenberg et al., 2007) . Tissue contrasts were examined by probing the inherent spin-spin (T 2 ) relaxation to obtain a series of T 2 -weighted images and subsequently to evaluate T 2 maps in the spinal cords and by means of T 1 -weighted imaging after injecting the contrast agent Gd-DTPA ( Figure 1C ; Figure S1B ). All WT spinal cords showed high contrast enhancement, particularly noticeable in the peripheral regions, whereas little contrast enhancement was observed with Irf8 À/À samples (see overlay images in Fig- ure S1B). T 2 values obtained from multiple slices in Figure 1D further reinforced greater enhancement in WT samples than Irf8 À/À samples. These results indicate that unlike WT mice that had extensive BBB breakdown, Irf8 À/À mice retained intact BBB. T cells were defective in differentiating into Th1 and Th17 cells after MOG immunization (Miyagawa et al., 2012; Ouyang et al., 2011 ). Conversely, it was possible that Irf8 À/À APCs fail to sensitize T cells and or provide a proper cytokine milieu to generate effector T cells. To assess the cell types through which IRF8 affects EAE, we tested mice with conditional Irf8 disruption. Irf8 f/f mice with LysM-cre should have monocyte-and macrophage-specific Irf8 disruption, wheras Irf8 f/f mice with Lck-cre should result in T cell-specific Irf8 disruption (Clausen et al., 1999; Feng et al., 2011) . We confirmed that in Irf8 f/f LysM-cre mice, expression of Irf8 mRNA and the protein was specifically depleted in macrophages and microglia ( Figure 3A , . However, noticeable IRF8 expression remained in the DC populations in these mice ( Figure 3A ), consistent with a previous report on the cell types affected by LysM-cre (Clausen et al., 1999) . Irf8 disruption in T cells was confirmed in our previous report (Ouyang et al., 2011) . Mice with monocyteand macrophage-specific Irf8 disruption remained resistant to EAE, although some mice displayed mild clinical signs after day 20 ( Figure 3B ). Irf8 +/+ LysM-cre mice, tested as a control, developed EAE, excluding nonspecific effects of Cre recombinase. Conversely, mice with T cell-specific Irf8 disruption developed EAE, showing similar clinical scores as WT mice or Irf8 f/f mice without Lck-cre ( Figure 3C ). These results indicate that IRF8 in the APCs of the monocyte and macrophage lineage is primarily responsible for causing EAE. IRF8 in T cells, however, although capable of regulating Th17 cells, does not have a consequential role in EAE (Ouyang et al., 2011) . To investigate whether IRF8 in DCs plays a role in EAE development, we performed adoptive-transfer experiments with bone marrow (BM)-derived DCs. Irf8 À/À mice, upon receiving WT BMDCs, displayed EAE clinical scores in the first 13 days, although scores were diminished thereafter ( Figure S3F ). These data support the role of IRF8 in macrophages and DCs in promoting EAE.
IRF8 Expression Increases in Macrophages, DCs, and Microglia during EAE
To identify the cells expressing IRF8 during EAE, we analyzed Irf8-EGFP gene-targeted mice, in which the IRF8-GFP fusion protein is expressed from the endogenous Irf8 promoter (details of these mice will be described elsewhere). When immunized with MOG, both homozygous and heterozygous Irf8-EGFP mice succumbed to EAE, exhibiting essentially the same clinical symptoms as WT mice ( Figure S4A ). This result is consistent with our previous report showing that the IRF8-GFP fusion protein functions in a manner identical to IRF8 (Laricchia-Robbio et al., 2005) . FACS analysis of GFP + cells in spleen from unimmunized mice showed that IRF8-GFP is expressed at high levels in DCs and macrophages, slightly lower levels in B cells, but at background levels in T cells and granulocytes (neutrophils) (Figure S4B ). IRF8-GFP was also expressed in microglia (CD11b + , CD45 lo ), a population distinct from macrophages (CD11b + , CD45 hi ) in the spinal cord ( Figure S4D ). IRF8-GFP + macrophages, DCs, and microglia were examined during EAE (Figure 4A) . The number of IRF8-GFP + microglia increased greatly during EAE along with a substantial increase in IRF8-EGFP expression, consistent with microglia activation during EAE ( Starossom et al., 2012) . Also in line with the inability of microglia activation in Irf8 À/À mice, mRNA expression of Cxcl9 (Mig1) and
Nos2 was much lower in Irf8 À/À spinal cords than in WT spinal cords, factors likely involved in neuronal inflammation and damage ( Figure S6B ) (Hauser and Oksenberg, 2006; Masuda et al., 2012) . IRF8-GFP + macrophages also increased in spinal cords during EAE, although numbers were lower than in microglia ( Figure 4A ). DCs in LN and spleen of unimmunized mice displayed two populations, IRF8-GFP hi and IRF8-GFP int , corresponding to plasmacytoid DCs/CD8a + DCs and myeloid DCs .The IRF8-GFP hi population increased in number as well as GFP intensity during EAE. IRF8-GFP expression in macrophages in LNs and spleens was also higher in EAE mice than in naive mice. Data in Figure 4B (left panel) showed that the number of total DCs and macrophages sharply increased on days 7 and 14, followed by a significant decline by day 21. As expected, the majority of these cells expressed IRF8-GFP ( Figure 4B, right panel) . Together, the total number and IRF8-GFP + APCs markedly increase in peripheral lymphoid organs and in spinal cords during EAE. Granulocytes, however, did not express IRF8 to a substantial degree throughout the course of EAE, suggesting that IRF8 in these cells does not play a major role in the disease. IRF8-GFP + T cells were very low in unimmunized mice, and only a small fraction of CD4 + or CD8 + T cells showed increased IRF8-GFP expression during EAE ( Figure S4C ).
Aberrant Production of IL-12 Family Cytokines in Irf8
-/-Mice Cytokines of the IL-12 family, IL-12 (p70), IL-23, and IL-27 are produced in APCs and influence the course of EAE (Vignali and Kuchroo, 2012) . IL-23, composed of IL-12p40 and p19, promotes Th17 cell expansion. Mice lacking either subunit or IL-23R are resistant to EAE (Becher et al., 2003; Chen et al., 2006; Cua et al., 2003) . IL-12(p70), a heterodimer of IL-12p40 and p35, affects Th1 cell development (Vignali and Kuchroo, 2012) . Alternatively, IL-27, composed of p28 and Ebi3, represses differentiation of Th17 and other T cells and reduces EAE pathogenesis (Batten et al., 2006; Stumhofer et al., 2006 ). Because we found that IRF8 in APCs, not T cells, accounts for EAE development, and because IRF8 has been shown to activate Il12b (IL-12p40) transcription in response to pathogens and TLR stimuli, it was possible that IRF8 promotes EAE by regulating these cytokines (Chang et al., 2012; Tailor et al., 2008) . We therefore tested mRNA expression of each subunit of the cytokines. As seen in Figure 5A , Il12b expression greatly increased in WT mice, but not in Irf8 À/À mice. In keeping with these data, IL12p40 protein expression in sera markedly increased in WT mice during EAE, but were near background in Irf8 À/À mice (Fig- ure 5B). Il23a (IL-23p19) and Il12a (IL-12p35) did not change greatly and was similar in WT and Irf8 À/À mice ( Figure 5A ; Figure S5A) . Given that the biological activity of IL-12 (p70) and IL-23 depends on IL-12p40, Irf8 À/À APCs fail to create an EAE promoting cytokine environment. Ebi3 mRNA levels also increased during EAE and were consistently higher in Irf8
mice than WT mice ( Figure 5A ). Il27 (IL-27p28) mRNA levels, also increased during EAE, were variable in WT and Irf8 À/À mice ( Figure S5A ). This might be due to the variable expression in non-APCs, because Il27 levels were higher in Irf8 À/À adherent cells than WT cells ( Figure S5B ). In accordance, IL-27 producing macrophages and microglia were much higher in Irf8 À/À mice compared to those in WT mice during EAE ( Figures 5C-5E ). IL-27 protein expression in sera was also higher in Irf8 À/À compared to WT mice during EAE ( Figure S5C ). The increase in IL-27 production might contribute to defective Th17 generation in Irf8 À/À mice, as evidenced by the following in vitro coculture assays: when CD4 + T cells were cultured with DCs obtained from day 21 EAE mice, addition of anti-IL-27 Ab increased Th17 cell generation and IL-17 induction with Irf8 À/À DCs to a greater extent than with WT DCs (see Figures S7F and S7G ). These 
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Multifaceted Role of IRF8 in Neuroinflammation results indicate that IRF8 supports production of cytokines favoring EAE, while repressing those that antagonize the disease.
avb8 Integrin Transcription in APCs Depends on IRF8 Whereas the above results pointed to the contribution of IL-12 family cytokines to EAE development, the complete absence of effector T cell differentiation in Irf8 À/À mice remained unexplained, suggesting an additional defect at an earlier, sensitization stage. APC activation of TGFb signaling is a key event in initiating Th17-cell development leading to EAE (Acharya et al., 2010; Melton et al., 2010) . This activity is mediated by integrin molecules of the avb8 subtype expressed on APCs. The avb8 integrin liberates biologically active TGF-b at the APC-T cell junction to achieve effective delivery of TGF-b into naive T cells, which in turn triggers Th17 cell differentiation (Acharya et al., 2010; Melton et al., 2010) . We postulated that IRF8 acts on this step by regulating transcription of Itgb8, the gene encoding the avb8 integrin. To test this hypothesis, we tested Itgb8 mRNA expression in macrophages and DCs sorted from WT and Irf8 À/À mice. Itgb8 was highly expressed in WT DCs and macrophages, but expression was striking lower in the Irf8 À/À counterparts ( Figure 6A ). Additionally, Itgb8 expression was induced by IFN-g and LPS stimulation both in WT BMDCs and BM-derived macrophages, but Itgb8 induction was meager in Irf8 À/À cells ( Figure 6B ). Luciferase reporter assays were performed to test IRF8 regulation of Itgb8 transcription in 293T cells transfected with an Irf8 expression vector ( Figure 6C ). The reporter containing the 1945 bp Itgb8 upstream fragment gave a robust luciferase activity, only when cotransfected with Irf8 vector (Figure 6D) . However, reporter activity by the 1081 bp fragment and the basal (null) promoter was low and not enhanced by Irf8, 
Multifaceted Role of IRF8 in Neuroinflammation suggesting that IRF8 enhances promoter activity through the region between À1,081 and À1,945. The region contains putative IRF8 binding sites resembling the IFN-stimulated response element (ISRE) ( Figure 6C ). When a mutation was placed in one of these sites (À1,945 mut, Site 1), IRF8 failed to enhance reporter activity, supporting the involvement of this site in Itgb8 transcription ( Figure 6D ). Chromatin immunoprecipitation (ChIP) assays were next performed for BMDCs from Irf8-EGFP gene-targeted mice with antibody against GFP and IRF8 ( Figure 6E ) for Site1 and two additional ISRE like sites, Site 2 and Site 3. Substantial IRF8 binding was detected on Site 1 by both antibodies, but IRF8 binding on other sites was meager to background. These results show that Itgb8 is a direct target of IRF8, which activates its transcription in APCs through Site 1.
IRF8 Activates Latent TGF-b and Triggers Development of Th17 and Treg cells
To test the possibility that IRF8 is involved in activation of TGF-b signaling in APCs to prime naive T cells, we examined development of Th17 cells in the presence of latent TGF-b from naive CD4 + T cells that were cultured along with CD11c + DCs in vitro. Flow cytometric analyses in Figure 7A (upper panel) and Figure S7B showed that with latent TGF-b, WT DCs, but not Irf8 À/À DCs, consistently stimulated Th17 cell development.
When cultured with active TGF-b, however, both WT and Irf8 Figure 7A ; Figure S7A ). Consequently, the amount of IL-17 secreted in supernatants was much lower when cultured with Irf8 À/À DCs and latent TGF-b, but comparable when cultured with active TGF-b ( Figure S7D ). Moreover, Irf8 À/À DCs did not stimulate Tregs generation when cultured with latent TGF-b, while WT DCs did, further supporting the idea that deficient TGF-b signaling accounts for the priming defects in Irf8 À/À DCs ( Figure 7B ). To verify the role of IRF8 in TGF-b signaling, we tested SMAD activation in APCs: among SMAD family of transcription factors activated by TGF-b signaling, SMAD2 is shown to be critical for Th17 cell activation (Malhotra et al., 2010) . As shown in Figure 7A (lower panel) and Figure S7C, Figure S7E ). Extending the above in vitro observations to in vivo, we found that SMAD2 phosphorylation was increased in CD4 + T cells upon EAE induction in WT mice, but not Irf8 À/À mice ( Figure 7C ). Moreover, Itgb8 and Irf8 transcript expression was enhanced in WT DCs during EAE, but negligible in Irf8 À/À DCs ( Figure 7D ). We also show that active TGF-b protein levels in sera were lower in Irf8 À/À mice than WT mice during EAE, whereas total TGF-b protein levels varied, although they tended to be lower in Irf8 À/À mice ( Figure 7E ). In addition, expression of Tgfb and Il6 mRNA was similar in WT and Irf8 À/À mice during EAE, indicating selective inability of
Irf8
À/À mice in producing biologically active TGF-b ( Figure S6A ).
These results provide compelling evidence that IRF8 is essential for TGF-b activation in APCs and hence sensitization of naive CD4 + T to differentiate into Th17 cells and Tregs.
DISCUSSION
We show that Irf8 À/À mice are resistant to EAE: Th17, Th1, and
Treg cells were not generated in Irf8 À/À mice upon MOG immunization. IRF8 in APCs, but not in T cells, promoted EAE pathogenesis in a multifaceted manner. We show several key mechanisms by which IRF8 promotes EAE, which likely constitutes a basis of the MS risk factor (De Jager et al., 2009; Disanto et al., 2012; Beecham et al., 2013) . IRF8 was required for TGF-b signaling that takes place at the interface between APCs and naive T cells. The bulk of secreted TGF-b is biologically inactive, as it is bound to the latency associated protein (LAP). However, the avb8 integrin molecule on the APC cell surface dissociates LAP to liberate functional TGF-b, allowing direct delivery of TGF-b signal to T cells (Acharya et al., 2010; Melton et al., 2010; Henderson and Sheppard, 2013) . This step, coupled with TCR engagement drives T cells to differentiate into Th17 cells (Acharya et al., 2010; Melton et al., 2010) . Our data show that IRF8 plays a role in this priming step by enhancing Itgb8 transcription in APCs. The conclusion that integrin-mediated TGF-b signaling depends on IRF8 is supported by the following observations: (1) Itgb8 transcript levels were markedly lower in Irf8 À/À APCs than WT cells, (2) IRF8 mice might further contribute to the absence of EAE (Chen et al., 2006; Pandiyan et al., 2011) . Together, in view of the noted requirement of TGF-b signaling for the EAE and for MS, IRF8 is likely to exert a decisive influence on the onset of the disease (Veldhoen et al., 2006) . Not only Th17 cells, but Th1 cells facilitate pathogenesis of EAE and MS (Axtell et al., 2010; Kroenke et al., 2008; LovettRacke et al., 2011) . Th1 cells prompt macrophage infiltration and NOS2 induction, whereas Th17 cells attract neutrophils and stimulate GM-CSF production (Kroenke et al., 2008) . Although Th1 cell development might or might not depend on TGF-b signaling, initial triggering of Th1 differentiation is likely to be compromised in Irf8 À/À mice as a result of the reduced expression of MHC II and costimulatory molecules on Irf8
APCs ( Figure S6C ). Our results show that in addition to priming, IRF8 exerts a major influence on subsequent stages of the disease, by facilitating expansion and maintenance of Th17 and Th1 cells through the regulation of IL-12 family cytokines. IL-12(p70) is critical for development of Th1 cells in EAE, whereas IL-23 is necessary for maintenance of Th17 cells (Becher et al., 2003; Cua et al., 2003; Kroenke et al., 2008) . IL-23 likely contributes not only to EAE but to MS, because it is produced by microglia of MS patients (Li et al., 2007) . Due to the absence of the shared IL-12p40 subunit, Irf8 À/À mice are defective in producing both IL-12p70 and IL-23, which would create an adverse environment for the survival of Th1 and Th17 cells. Interestingly, Irf8 À/À APCs expressed greater levels of IL-27 than WT cells, the cytokine that negatively regulates development of Th17 and other T cells . Expression of Ebi3 mRNA was significantly increased in Irf8 À/À APCs relative to WT cells during EAE. Irf8 À/À mice had greater number of IL-27p28 + macrophages and microglia than WT mice. Together, IRF8 appears to facilitate pro-Th1/Th17 cytokines and inhibits the anti-Th17 cytokine, generating a condition favoring inflammation and exacerbation of EAE. The increase in IL-27 expression in Irf8 À/À mice was somewhat unexpected, considering the previous report that IRF8 enhances IL-27p28 transcription in macrophages after TLR stimulation in vitro, while not affecting Ebi3 expression (Zhang et al., 2010) . The different results obtained in the two studies might be due to the differing cytokine environments in which IL-27 expression was examined, one in vitro after TLR stimulation, the other in vivo after MOG immunization, because it was previously found that IRF8 can act as a transcriptional activator or a repressor in macrophages, depending on stimulation (Chang et al., 2012) . In addition, binding partners for IRF8, such as IRF1, might also affect target gene regulation (Horiuchi et al., 2012) . In this respect, it is interesting to note that Irf1 À/À mice are partially resistant to EAE, suggesting the possibility that IRF1 might cooperate with IRF8 to exacerbate EAE (Tada et al., 1997) .
Microglia, the CNS-resident APCs, are activated in EAE and play a role in disease progression (Starossom et al., 2012) . Analysis of Irf8-EGFP knockin mice found that the number of IRF8-GFP + microglia and levels of IRF8-GFP increased during EAE. Although microglia are present in the CNS of Irf8 À/À mice, they express reduced levels of Iba1 and other microglia markers and are deficient in IL-12p40 induction in vitro (Horiuchi et al., 2012; Minten et al., 2012) . Moreover, IRF8 is shown to be important for transforming quiescent microglia to a reactive phenotype that produces proinflammatory cytokines after peripheral nerve injury (Masuda et al., 2012) . In agreement, our results show that IRF8 plays a key role in microglial activation during EAE by stimulating IL-12p40 expression, which in turn increases intra-CNS amplification of Th1 and Th17 cells. We also noted that Irf8 À/À microglia produce more IL-27 than WT mice. Thus, the ability to activate microglia might be another attribute of IRF8 that boosts EAE disease progression. IRF8 might reinforce disease by enhancing expression of Ripk2 in CNS-infiltrating DCs (Shaw et al., 2011) . In light of the recent report that IRF8 promotes Ly6C + monocyte differentiation (Kurotaki et al., 2013) , which supports proinflammatory M1-type macrophages, IRF8 appears to have a strong propensity to steer APCs toward proinflammatory pathways and advance EAE progression. Lastly, it should be noted that IRF8 SNPs linked to the MS susceptibility map to the 3 0 noncoding region of the IRF8 gene, away from the transcription end sites (De Jager et al., 2009; Disanto et al., 2012) . This suggests that the SNPs are in a downstream regulatory sequence(s) yet to be fully characterized, which influences IRF8 transcription in APCs. It will be of interest to elucidate how this region affects IRF8 transcription and whether drugs currently used or proposed for MS treatment affect IRF8 expression.
In conclusion, IRF8, acting in APCs, activates TGF-b signaling and primes naive T cells to initiate EAE. During the course of disease, IRF8 fortifies inflammatory pathways to exacerbate EAE pathogenesis. Together, this work highlights the multiplicity of mechanisms by which IRF8 functions as a risk factor for MS.
EXPERIMENTAL PROCEDURES Mice and EAE Irf8
À/À , Irf8-EGFP, and Irf8 f/f mice of the C57BL/6 background and WT mice were maintained in the NICHD animal facility (Feng et al., 2011) f/f Lck-cre mice (Clausen et al., 1999; Jakubzick et al., 2008) . All animal experiments were performed according to the animal study approved by the Animal Care and Use Committees of NICHD, NIH. Female mice (8-12 weeks old) were injected with 200 mg MOG in CFA containing 400 mg of killed M. tuberculosis subcutaneously at two sites and intraperitoneally with 100 ng of pertussis toxin, followed by injection of 100 ng pertussis toxin 24 hr later (Hooke Laboratories). EAE symptoms were scored daily according to the EAE scoring system.
Magnetic Resonance Imaging
MRI experiments were performed on a 7-T (Bruker Avance), 21 cm horizontal scanner. A contiguous set of 1 mm thick, T 1 weighted images (field-of-view [FOV] = 25.6 3 12.8 mm, in-plane resolution of 100 mm, TE/TR = 6/100 ms), encompassing the region between the Th9-L5 vertebrae (15 slices), were acquired before and 5 min after intravenous administration of Gd-DTPA (Berlex Laboratories). Quantitative T 2 images (TE/TR = 20/2500 ms, in-plane resolution of 200 mm, number of echoes = 16) were acquired with the same number of slices and slice locations as the T 1 -weighted images. T 2 data were analyzed with software by MATLAB (Mathworks Inc). The resultant T 2 maps were used to evaluate T 2 values for four regions of interests (area 0.016 cm 2 ) per slice.
Cell Preparations, Culture, and Flow Cytometry Microglia-macrophage populations were prepared from spinal cord single-cell suspensions by a 37%/70% percoll density gradient centrifugation, followed by incubation on tissue culture plates for 1 hr. CD11c + DCs were isolated from draining LN and spleen (90%-95%) as described Acharya et al., 2010; Melton et al., 2010) . Naive CD4 + T cells were isolated from LN of WT mice with biotin-conjugated anti-CD8a, CD11b, CD11c, CD19, CD45R, NK1.1, Gr-1 Abs (Biolegend), and streptavidin microbeads (Miltenyi Biotec). For Th17 development, 2.5 3 10 5 T cells were cultured with 10 5 DCs for 5 days with anti-IL4 (10 mg/ml, Bio X cell), anti-IL-12 (10 mg/ml, Bio X Cell), anti-IFN-g (10 mg/ml, Bio X Cell), anti-CD3 (1 mg/ml, eBiosciences), IL-6 (10 ng/ml, Pepro Tec), IL-1b (10 ng/ml, Pepro Tec), and TGF-b1 (5 ng/ml, R&D Systems) or latent TGF-b1 (5 or 20 ng/ml, R&D Systems), supplemented with fresh media on day 3. For Treg development, cells were cultured with anti-IL-4 (10 mg/ml, Bio X cell), anti-IL12 (10 mg/ml, Bio X Cell), anti-IFN-g (10 mg/ml, Bio X Cell), anti-CD3 (1 mg/ml, eBiosciences), anti-CD28 (3 mg/ml, eBiosciences), IL-2 (100 U/ml, Pepro Tec), and TGF-b1 (5 ng/ml, R&D Systems) or latent TGF-b1 (5 or 20 ng/ml, R&D Systems). Transcripts were measured by quantitative RT-PCR and normalized by Hprt as described (Chang et al., 2012) . The concentrations of IL-12p40, IL-27, and TGF-b1 in sera from MOG-immunized mice were measured by ELISA using commercial kits (eBioscience and R&D Systems). Flow cytometry cells were blocked with anti-mouse FcgR Ab (CD16/32, clone 2.4G2), stained with Abs below, and analyzed on FACSCalibur (BD Biosciences). Data were analyzed by FlowJo software. The following antibodies were used: PerCP-conjugated anti-CD4, allophycocyanin-conjugated anti-CD25 Abs (BD Biosciences), allophycocyanin-conjugated anti-F4/80, PE-conjugated anti-CD11b and PerCP-conjugated anti-CD45 Abs, BD Biosciences), PE-conjugated anti-IL17, FITC-conjugated anti-IFN-g (BD Biosciences) and FITC-conjugated anti-IL27 Abs (R&D Systems) with Cytyofix/Cytoperm kits (BD Biosciences), or allophycocyaninconjugated anti-RORgt, PE-conjugated anti-FOXP3 Abs (eBiosciences), and PE-conjugated anti-Phospho SMAD3/2 Abs (BD Biosciences). To purify DCs and macrophages, we treated spleen cell suspensions with the Fc receptor blocker 2.4G2 mAb followed by staining with antibodies against Gr-1, CD11c, MHC II, CD11b, and F4/80 and sorted with a FACSAria-sorter (BD Biosciences BMDCs was immunoprecipitated with 0.5 to 1 mg of normal immunoglobulin G (IgG), affinity purified anti-IRF8 antibody, or anti-GFP antibody bound to Dynabeads (Chang et al., 2012) . The following primers were used for site 1: 
